CRNX logo

CRNX
Crinetics Pharmaceuticals Inc

1,452
Mkt Cap
$3.91B
Volume
270,810.00
52W High
$57.99
52W Low
$25.83
PE Ratio
-7.23
CRNX Fundamentals
Price
$37.01
Prev Close
$37.09
Open
$36.96
50D MA
$37.83
Beta
1.18
Avg. Volume
1.08M
EPS (Annual)
-$4.95
P/B
3.05
Rev/Employee
$12,956.23
$3,399.01
Loading...
Loading...
News
all
press releases
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?
Key PointsADAR1 Capital Management added 829,963 shares of Crinetics Pharmaceuticals; estimated trade size $37.07 million based on quarterly average pricing...
News Placeholder
More News
News Placeholder
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates
CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -0.82% and +42.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Will Aquestive Therapeutics (AQST) Report Negative Q1 Earnings? What You Should Know
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
News Placeholder
Jennison Associates LLC Sells 763,133 Shares of Crinetics Pharmaceuticals, Inc. $CRNX
Jennison Associates LLC reduced its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 37.3% in the fourth quarter, according to the company in its most recent Form 13F filing...
News Placeholder
Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for
CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
News Placeholder
Pictet Asset Management Holding SA Has $72.63 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX
Pictet Asset Management Holding SA lifted its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 6.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,560,300 shares of the...
News Placeholder
Crinetics Pharmaceuticals (NASDAQ:CRNX) Given New $97.00 Price Target at Citizens Jmp
Citizens Jmp upped their target price on Crinetics Pharmaceuticals from $96.00 to $97.00 and gave the company a "market outperform" rating in a research report on Tuesday...
News Placeholder
Impax Asset Management Group plc Buys Shares of 275,000 Crinetics Pharmaceuticals, Inc. $CRNX
Impax Asset Management Group plc bought a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the fourth quarter, according to the company in its most recent...
News Placeholder
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Rating of "Moderate Buy" by Analysts
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the ten research firms that are presently covering the...
News Placeholder
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
Amneal (AMRX) delivered earnings and revenue surprises of +63.64% and +1.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available